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Cardiac stem/progenitors are being used in the clinic to treat patients with a range of cardiac 
pathologies. However, improvements in heart function following treatment have been reported to 
be variable, with some showing no response. This discrepancy in response remains unresolved. 
MSCs have been highlighted as a regenerative tool as these cells display both immunomodulatory 
and pro-regenerative activity. The purpose of this study was to derive a cardiac MSC population to 
provide an alternative/support to current therapies.  We derived human cardiac-mesenchymal-
stem-cell-like-cells (CMSCLC) so named as they share some MSC characteristics. However, CMSCLC 
lack the MSC tri-lineage differentiation capacity, being capable of only rare adipogenic 
differentiation and demonstrating low/no osteogenic or chondrogenic potential, a phenotype that 
may have advantages following transplantation. Further, CMSCLC expressed low levels of p16, high 
levels of MHCI and low levels of MHCII. A lack of senescent cells would also be advantageous for cells 
to be used therapeutically, as would the ability to modulate the immune response. Crucially, 
CMSCLC display a transcriptional profile which includes genes associated with cardio-
protective/cardio-beneficial effects.  CMSCLC are also secretory and multipotent, giving rise to 
cardiomyocytes and endothelial cells. Our findings support CMSCLC as a novel cell population 











Cellular strategies using bone marrow-derived cells or autologous cardiac derived cells have translated 
into the clinical setting as potential therapies for the treatment of patients with heart failure [1-3]. 
Although these trials have demonstrated some benefits of these therapies, they are also not without 
limitations, with reports of only modest improvements in cardiac function in some patients and no 
improvements in others. The mechanisms behind the improvements that have occurred remain 
unclear, it has been postulated that these transplanted cells either contribute to regeneration 
themselves giving rise to new cardiomyocytes or that they secrete paracrine factors to support native 
cardiac cells, spared by injury, allowing these cells to recover and promote some level of cardiac 
regeneration. Regardless of the mechanism, a better understanding of these cells may lead to 
improvement in cardiac regeneration. However, the choice of the most appropriate cell population 
for this application has as yet to be determined. Mesenchymal stem cells (MSCs) have been selected 
as a useful cell population for tissue regeneration as they have been reported to be safe, have 
immunomodulatory effects and to secrete pro-regenerative factors [4-8]. Human sub-endocardial 
MSCs have been derived, this cell population was capable of expansion in vitro, expressed markers 
normally expressed by MSCs and was capable of multi-lineage differentiation to osteoblasts, 
adipocytes and chondrocytes. Moreover, these cells express cardiac transcription factors while lacking 
expression of markers associated with mature cardiomyocytes [9].  
In this study we aimed to determine if we could isolate a cardiac cell population using tissue that is 
normally discarded as surgical waste (and therefore not necessitating any additional invasive 
procedures) from which we could derive cells that were MSCs or had MSC-like qualities and might 
therefore make them a more optimal tool to study cardiac regeneration. We opted for specimens of 
right atrial appendage (RAA) which are excised during coronary artery bypass surgery. RAA has 
previously been described as having characteristics of both atrial and ventricular tissue [10] and has 
been used as a source of stem cells used in a clinical trial [1]. We isolated a stem cell population that 
we have termed cardiac-derived mesenchymal stem cell-like cells (CMSCLC) and compared these with 
cardiosphere-cardiac-derived cells (CS-CDCs) (also RAA derived) and to bone marrow-derived MSCs. 
We demonstrate that while these CMSCLC are similar to other reported MSC cell populations e.g. have 
an MSC like morphology; they also differ as they are largely incapable of the tri-lineage differentiation 
normally displayed by MSCs. Some CMSCLC could be made to differentiate into cells of the adipogenic 
lineage, and while displaying the morphology of osteoblasts under osteogenic culture conditions, 
contributed to no or negligible matrix mineralisation, and under chondrogenic culture conditions did 
not undergo chondrogenesis. This was in contrast to CS-CDCs which differentiated readily to the 
osteogenic lineage, while also only displaying a low level of adipogenic lineage differentiation 
potential. However, both CMSCLC and CS-CDCs under in vitro cardiac differentiation conditions 
displayed morphological changes indicative of a more mature cardiac lineage cell, while the CMSCLC 
also showed early striation formation. In addition we show that some CMSCLC express the senescence 
marker p16. We also undertook transcriptional analysis of single CMSCLC cells from three individual 
human heart tissue donors and showed that they expressed at varying levels; genes associated with 
pluripotency, proliferation, migration, differentiation, endothelial cells, cardiogenesis and 
cardioprotective factors. This data provides further support for results obtained using a range of other 
techniques employed in this study. Taken together our data suggests that these CMSCLC cells differ 
from CS-CDCs. CMSCLC have a more limited ability to differentiate to non-cardiac cell lineages than 




All studies were performed according to the amended Declaration of Helsinki. All cardiac tissue 
samples were collected from consenting patients undergoing cardiac surgery at the James Cook 
University Hospital, Middlesbrough, UK. Approval for collection and use of tissue was given by Local 
ethics committee under REC number UKCRN ID: 20120092. 
 
Derivation and culture of CMSCLC 
Right atrial appendage (RAA) (from 5 patients, 3 males - ages 62 (patient number 1179),  66 (patient 
number 1201) and 73 (patient number 1201) and two females aged 66 (patient number 1114)  and 78 
(patient number 1132)) all undergoing coronary artery bypass surgery) was washed and chopped 
followed by digestion for 45 minutes in 0.01% (wt/vol) pronase (Calbiochem), during which the tissue 
suspension was rotated on a MACSrotator (Miltenyi) at 370C and then tissue was dissociated using a 
gentleMACS dissociator (Miltenyi). The resulting cell suspension was then filtered thought a 70 µm 
cell strainer (BD). Cardiac cell suspensions were made up to a total of 6ml with MSC medium (αMEM, 
10% (vol/vol) FBS, 1% (vol/vol) Glutamax™, 5ng/ml FGF2, (Peprotech), seeded into T-25 culture flasks 
and cultured at 5% CO2, 5% O2. The culture medium was removed 72 hours post-seeding and non-
adherent cells were removed by rinsing 3 times with DPBS. Fresh culture medium was added and 
further medium changes were performed every three days thereafter. Colony-forming unit fibroblasts 
(CFU-Fs) where defined as colonies if they contained 50 or more cells. CFUs were observed 
approximately 15 days post-seeding, these ranged from 8-11 CFUs per CMSCLC culture and 18 CFUs 
for bone marrow (Figure 1). All colonies from each individual donor were expanded as a pool until 
confluent. Upon confluence, cell cultures were expanded by passage at a ratio of 1:3 using TrypLE™ 
Express. 
 
Cell population doublings of CMSCLC 
Cell population doubling of CMSCLC per day were calculated over three cell passages, equation to 
calculate this is provided under the statistics heading and based on [11]. 
 
Derivation and culture of cardiac derived cells from cardiospheres 
Cardiospheres were derived using methods described previously [12]. In brief, RAA (from 3 patients, 
1 female aged 84 and 2 males aged 59 and 65 all undergoing coronary artery bypass surgery) were 
minced into small <1mm3 fragments in trypsin and transferred to fibronectin coated plates in DMEM 
with 20% serum containing 0.1 mmol/l 2-mercaptoethanol (GIBCO). Following culture, for 10 days, 
non-adherent phase bright cell were harvested and cultured on Poly-D-Lysine in cardiosphere growing 
media. Several days later, cells that remained adherent to the poly-D-lysine coated dishes were 
discarded, while detached cardiospheres were harvested and expanded as a monolayer of CDCs on 
fibronectin coated plates. 
 
Derivation and culture of bone marrow-derived MSCs 
Bone marrow mononuclear cells (BMMNCs) were purchased from Lonza (27 year old male donor). 
BMMNCs were resuspended in MSC medium, seeded at a density of 1.25 x107 cells/T-75 flask and 
cultured at 5% CO2, 5% O2. The culture medium was removed 72 hours post-seeding and non-
adherent cells were removed by rinsing 3 times with DPBS. Fresh culture medium was added and 
further medium changes were performed every three days thereafter. Upon confluence, cell cultures 
were expanded by passage at a ratio of 1:3 using TrypLE™ Express. 
 
Immunophenotyping of MSCs 
Cardiac cells were detached from tissue culture plastic using TrypLE™ Express and resuspended in 
FACS buffer to a cell density of 1 x 106 cells/ml. Aliquots of 200µl were transferred to 1.5ml microfuge 
tubes and incubated at 4°C for 1 hour with 5µg/ml of primary antibody (CD44, CD90, CD105, CD106, 
CD146, CD166, CD19, CD45 or IgG isotype control). Primary antibodies and IgG control were taken 
from the Human Multipotent Mesenchymal Stromal Cell Marker Antibody Panel kit (R&D Systems). 
Cells were rinsed with PBS and then resuspended in FACS buffer with donkey anti-mouse secondary 
antibody conjugated to Alexa Flour® 488 diluted 1:250 (Invitrogen). Cells were labeled with directly 
conjugated primary antibodies raised against MHC class I and MHC class II antigens (HLA-ABC-FITC, 
5µl of stock reagent in 200µl of cell suspension, Beckman Coulter; PE mouse antihuman HLA-DR 5µl 
of stock reagent in 200µl of cell suspension, BD) and c-kit (5µg/ml of PE conjugated primary antibody; 
BD) Controls where unstained CDC and CMSCLC from the same cell preparations.  Analysis was done 
using a FACS Canto II (BD) using a 488 laser and 530/30 emission filter and data analysis collated using 
FACS DiVa software.   
 
Analysis of PDGFR-alpha expression by CMSCLC 
Cells were prepared and analyzed as for immunophenotyping. Primary antibody used was 5µg/ml of 
anti-human PDGFR-alpha (R&D systems, MAB322) and secondary was donkey anti-mouse secondary 
antibody conjugated to Alexa Flour® 488 diluted 1:250 (Invitrogen). 
 
Chondrogenic differentiation of cell populations 
Chondrogenic differentiation of cell populations was performed as previously described [13], with 
slight modification. Briefly, cells were collected by enzymatic detachment from tissue culture plastic 
and centrifugation at 700 x g for 3 minutes. Cells were resuspended in chondrogenic medium at a cell 
density of 5 x 105 cells/ml. Aliquots of 1ml volume were dispensed into 15ml conical tubes and cell 
aggregates formed by centrifugation at 700 x g for 3 minutes. The caps were loosened to allow for gas 
exchange and the cultures incubated at 5% CO2, 5% O2 for 14 days with medium changes every 2 days. 
 
Osteogenic differentiation of cell populations 
Osteogenic differentiation of cell populations was performed as previously described [14]. Briefly, cells 
were seeded in MSC medium into 12 well tissue culture plates at a density of 2.5 x 103 cells/cm2. 
Twenty-four hours post-seeding the medium was replaced with osteogenic medium. Cultures were 
maintained for 28 days at 5% CO2, 5% O2 with medium changes performed every 3-4 days.    
  
Adipogenic differentiation of cell populations 
Adipogenic differentiation of cell populations was performed using the StemPro® Adipogenesis 
Differentiation Kit (Gibco) as per manufacturer’s instructions; cultures were maintained under 
standard oxygen conditions for a total of 21 days.  
 Histological evaluation of differentiated cell populations 
Adipogenic cultures were evaluated by phase contrast microscopy and adipogenic cells identified as 
cells with prominent clusters of cytoplasmic lipid vesicles at 21 days for cardiac cells these were then 
stained with oil red O. Adipogenic cultures were incubated for 30 minutes at room temperature with 
oil red O (stock solution of 30% (vol/vol) oil red O in isopropanol diluted to 60% (vol/vol) in ddH2O. 
Excess oil red O solution was removed and the cultures rinsed with ddH2O. Osteogenic cultures were 
evaluated for matrix mineralisation by alizarin red staining. Osteogenic cultures were incubated for 2 
hours at room temperature in 2% (wt/vol) alizarin red (pH 4.3 with 10% (vol/vol) ammonium 
hydroxide). Excess alizarin red solution was removed and the cultures rinsed extensively with DPBS to 
remove background staining. Chondrogenic cell aggregates were embedded in OCT cryopreservation 
medium and frozen on dry ice. Cryosections (7 µm) were cut onto slides for histological analysis of 
cartilage tissue formation. For Safranin O staining, cell pellet sections were stained with Harris’ 
hematoxylin for 4 minutes, de-stained in acid alcohol (1% vol/vol HCl, 70% (vol/vol) for 10 seconds 
and rinsed in deionised water. Sections were counter-stained with 0.02% aqueous fast green FCF for 
3 minutes, rinsed in 1% (vol/vol) acetic acid and then stained with 0.1% aqueous Safranin O for 5 
minutes. The slides were rinsed, dehydrated and mounted using DePeX mounting medium. 
 
Cardiac differentiation of cell populations 
CS-CDCs and CMSCLC were seeded into 12 well tissue culture plates at a density of 2.5 x 103cells/cm2 
and placed under their respective culture conditions. After 3 days, the culture medium was replaced 
with cardiac differentiation medium (Cellutions) and this in turn was replaced every 4 days. After 7 
days in cardiac differentiation medium the differentiating CMSCLC cultures were transferred to 
incubation at 5% CO2, 22% O2 for a further 14 days of culture.  
 
Endothelial cell differentiation of CMSCLC – CMSCLC were derived as described above and then 
cultured in Endothelial Cell Growth Medium 2 (Promocell) for 9 days under standard oxygen 
conditions, with medium being replaced every 3 days.  
 
Immunocytochemistry 
Cardiac differentiated cells grown either on coverslips or in chamber slides were harvested after two 
or three weeks in cardiac differentiation media, rinsed with DPBS and fixed in cold methanol at -20°C 
for 20 minutes. Primary antibodies used were Cardiac troponin C 1:200 (Abcam, Ab30807), NXK2.5 
1:200 (Abcam, Ab35842), alpha Tropomyosin 1:200 (GeneTex, GTX113857) and Cardiac Actin 1:200 
(GeneTex, GTX101876). The secondary antibodies used were, donkey anti goat-AF488 (Invitrogen A-
11055), donkey Anti-Rabbit AF594 (Invitrogen ab150076) and donkey anti rabbit-AF488 (Invitrogen 
A11008). Negative controls were sections incubated as for primary staining but without the inclusion 
of primary antibodies. As a positive control cells of the AC10 cell line (derived from adult human 
ventricular cardiomyocytes) [15] where also stained will the aforementioned antibodies. For Confocal 
Z-stack imaging a Nikon Eclipse Ti was used running NIS Elements AR 4.20.02 software.  
Endothelial cell differentiation cells, were grown in chamber slides for 9 days, medium removed and 
cells fixed in ethanol for 10min.  Cells were immunostained for CD34 (1:250; M7165; Dako Cytomation) 
using an avidin-biotin-peroxidase technique (Vectastain Elite ABC kit; Vector Laboratories) and the 
reaction developed for 1-2 min with 3,3′-diaminobenzidine (DAB; Sigma) containing 0.01% H2O2 to 
give a brown reaction product. Sections were lightly counterstained with Mayer’s haematoxylin for 30 
sec, dehydrated, cleared in xylene and mounted with DPX synthetic resin. 
CMSCLC for senescence analysis at passage 3 where maintained under standard MSC culture 
conditions in chamber slides for 24 hours and then fixed. Primary antibody used was p16 1:50 (Santa 
Cruz, J0411), secondary was Donkey anti-Rabbit IgG (H+L), Alexa Fluor 488 (A-21206 Thermofisher) 
(1/1000). Under x20 magnification 5 distinct fields of cells were imaged using an Axio imager 2 
microscope (Zeiss) and the percent of positive p16 expressing cells determined from these images. ICC 
images to show p16 where obtained using a confocal Nikon Eclipse Ti using NIS Elements AR 4.20.02 
software as mentioned above. 
 
In vitro protein expression quantification. 
Following staining with NKX2.5 and troponin C antibodies, cultures were imaged at random locations 
(n>5). Using ImageJ software (ImageJ; U.S. National Institutes of Health; http://rsbweb.nih.gov/ij/) 
total cell numbers were counted based on DAPI stained nuclei. Percentage positive cells for each 
protein was calculated based on number of cells labelled with the specific antibody as a percentage 
of the total cell numbers. All quantification were performed in a blinded manner. 
 
Polymerase chain reaction (PCR)  
PCR was performed as described previously [16], PCR was run for 25 and 35 cycles in order to ascertain 
that comparisons of expression were made at the exponential phase and not once cDNA amplification 
had plateaued, data is shown for 35 cycles. The primer sequences used were as follows: MEF2C 
forward: CGAGATACCCACAACACACG, reverse: CGCTTGACTGAGGGACTTTC, GATA4 forward: 
TCCCTCTTCCCTCCTCAAAT, reverse: TCAGCGTGTAAAGGCATCTG, β-actin forward: 
GCGGGAAATCGTGCGTGAC, reverse: GGAAGGAAGGCTGGAAGAG. 
 
ELISA analysis 
Cell culture supernatants (control was MSC media only) from CMSCLC at day 14 and day 17 of culture 
were analysed for IL-10, VEGF, FGF2 and TGFβ1 secretion by ELISA according to the manufacturer’s 
instructions (IL-10, VEGF, FGF2, TGFβ1 Duosets; R&D). 
 
Single cell capture  
Single cells were captured and the loci of interest pre-amplified using the C1 system (Fluidigm, 
software version 2.2.1) following the manufacturers protocol. Cells were partitioned using a 10-17 µm 
C1 Single-Cell Preamp integrated fluidic circuit (IFC) (Fluidigm PN 100-5479). IFC priming, cell loading 
and lysis, reverse transcription and pre-amplification was then carried out using reagents from the 
following kits; C1 Single-Cell Auto Prep Reagent Kit (Fluidigm PN 100-5139), Ambion Single Cell-to-CT 
qRT-PCR Kit (Thermo Fisher Scientific 4458237) and 20X TaqMan Gene Expression primers (Thermo 
Fisher Scientific). Amplicons were transferred from the IFC to a 96 well plate and stored at -20°C. 
 
Single cell gene expression analysis 
Single cell gene expression analysis was carried out using the Biomark HD system and IFC Controller 
HX (Fluidigm) as per manufacturer’s instructions. Gene expression analysis was carried out using 
Dynamic Array Flex Six Gene Expression IFCs (Fluidigm). Assays were run using reagents from the 
following kits; Flex Six Gene Expression Reagent Kit (Fluidigm), 20X TaqMan Gene Expression primers 
(Thermo Fisher Scientific) and TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific). TaqMan 
primers used are listed in Supplemental Table 1. 
 
Analysis of single cell data 
CT values were calculated using the Fludigm Real-time Analysis software. The remainder of the 
analysis was carried out using Data analysis was carried out primarily in R (version 3.4.1) and the 
expression values extracted using SINGuLAR Analysis Toolset v3.6.2. Low quality cells were excluded 
from the analysis if total expression per cell was less than 250; or the number of detected genes per 
cell less than 10. The filtered data was normalised using the computeSumFactors from the Scran R 
package. The remainder of the analysis was carried out using R core functions.  
 
Statistical analysis 
Cell population doubling of CMSCLC per day were calculated over three cell passages using the 
following equation [26], population doublings per day = ln N / N0 x t-1. Where N0 = number of cells 
seeded, N = number of cells counted at passage, t-1 = number of days to passage. Percentage of p16 
expressing cells was determined using SPSS box plot analysis. Excel 2013 was used to generate bar 
chart for single cell data. 
 
Results 
Morphological, CFU forming potential and doubling time of CMSCLC 
CMSCLC were examined to determine if they had MSC like characteristics when cultured under 
standard MSC culture conditions. At passage 3 bone marrow-derived MSC (BM-MSCs) were plastic 
adherent and displayed a distinct fibroblast like morphology (Fig. 1A), CMSCLC also displayed these 
characteristics at passage 3 (Fig. 1 B-D). The morphology of CS-CDC cells is also show as a comparison 
to the CMSCLC (1E). Colony forming potential is a recognised stem cell characteristic, an example of a 
CFU is shown (Fig. 1F). CMSCLC from 3 different patient derived cultures readily formed similar 
numbers of CFUs around day 15 post seeding into culture (Fig.1G) as a control BM-MSCs were also 
used and formed CFUs at day 7 post seeding in vitro, CFUs where counted at day 15 (Fig. 1G). Cell 
doubling rates of CMSCLC were also determined for all 3 patient derived cell cultures and no significant 
difference in doubling rates was observed (Supplemental Fig.1).  
 
Phenotyping of CMSCLC 
CDCs and CMSCLC were screened for expression of cell surface antigens known to be expressed by 
MSCs. Both cell populations expressed CD44, CD105 and CD166 but the CDCs express all these markers 
at much lower levels than the CMSCLC (Fig 2), while both expressed low levels of the hematopoietic 
lineages markers CD19 and CD45 (Fig. 2). Controls included IgG isotype control and unstained CDC and 
CMSCLC (Fig. 2).  CMSCLC were also tested for the expression of MHC I and II.  Representative images 
of the data generated are shown in (Fig. 3A) demonstrating the majority of cells expressed MHC I (98%) 
and lacked expression of MHC II (0.4%). Controls included IgG isotype control stained and unstained 
CMSCLC (data not shown). Three different patient-derived CMSCLC cultures were analyzed for MHC 
expression and the percentages of positive cells per culture are shown in (Fig. 3B). CMSCLC were also 
examined for expression of c-kit, this analysis revealed the presence of c-kit expression in only a rare 
sub-population of cells (0.5% - 2.6%) (Fig 3C and Table). Controls were CMSCLC stained with IgG 
isotype control only and unstained cells (data not shown). In addition to immunophenotyping, the 
CMSCLC they were also immunostained (after nine days in culture) for the expression of CD34. Cells 
from the same donor derived CMSCLC line cultured under normal CMSCLC culture conditions showed 
no/low CD34 expression, while cells cultured under endothelial cell differentiation conditions showed 
increased expression of CD34 (Fig 3D). We also examined CMSCLC for expression of PDGFR-alpha and 
showed that some cells express this marker (Supplemental figure 2). 
 
Secretion of IL-10, VEGF, FGF2 and TGFβ1 by CMSCLC 
To determine if CMSCLC secreted IL-10, VEGF, FGF2 and TGFβ1 CMSCLC were cultured under normal 
CMSCLC conditions as described above and media was collected at day 14 and 17 of culture. In all 
cases there was an increase in fold expression when compared to control media. After 14 days culture 
there was a 1.3 fold increase in IL-10 secretion, but by day 17 there was a 4.5 fold increase in IL-10 
secretion. For VEGF at day 14 there was a 13.5 fold increase in VEGF secretion which dropped to an 
11.7 fold increase at day 17 compared to control, whereas for FGF2 at both day 14 and 17 there was 
an 8.9 fold increase compared to control. For TGFβ1 there was a 1.5 fold increase at both times points 
compared to control (Supplemental Fig. 3A). In all cases except for IL10 at day 14 the increase in 
expression compared to control was significant (Supplemental Fig. 3B). 
 
Osteogenic, adipogenic and chondrogenic differentiation potential of CMSCLC 
To determine the differentiation potential to the above-mentioned lineages CMSCLC, CDCs and BM-
MSCs were cultured under the appropriate lineage differentiation conditions. Cultures were examined 
microscopically for morphological changes, both CDCs (Fig. 4A) and CMSCLC (Fig. 4B) underwent 
morphological changes when cultured for 28 days under osteogenic culture conditions but when 
stained for matrix mineralization using alizarin red only the CDCs cultures stained (Fig. 4C) whereas 
the CMSCLC showed low/no positive staining (Fig. 4D).  Adipogenic differentiation was determined by 
the presence of cells with prominent clusters of cytoplasmic lipid vesicles that stained positively with 
Oil red O after 21 days in culture (Fig. 4E and 4F). When cultured under chondrogenic culture 
conditions at 14 days the CDCs (Fig. 4G) and CMSCLC (Fig. 4H) formed aggregates but when evaluated 
histologically failed to stain with Safranin O, and had not undergone chondrogenic differentiation. BM-
MSC cultured under the same tri-lineage differentiation culture conditions provided a control and 
successfully differentiated to; the osteogenic lineage and displayed matrix mineralization as indicated 
by alizarin red staining (4I) the adipogenic lineage as indicated by Oil red O staining of cells containing 
cytoplasmic lipid vesicles (4J) and to the chondrogenic lineage as shown by staining of aggregates with 
Safranin O (4K). 
 
Expression of p16 by CMSCLC 
In order to establish if the level of senescence was higher in some patients CMSCLC than others, we 
compared the level of senescence from CMSCLC at passage 3 from 3 different patients. The cultures 
were stained using p16 antisera. A representative image of p16 stained cells in a CMSCLC culture is 
shown (Fig. 5A). All cultures contained low percentages of p16 expressing cells (Fig. 5B). 
 
Cardiac differentiation potential of CMSCLC 
To determine the ability of CMSCLC to differentiate to a more mature cardiac lineage, cells were 
cultured under cardiac differentiation conditions, after two weeks the cells were stained for cardiac 
troponin I and NXK2.5 expression. CDCs have a previously demonstrated cardiogenic potential, and 
were used as a positive control being cultured under the same cardiac differentiation conditions for 
the same length of time. For both the CDCs (Fig. 6A) and CMSCLCs (Fig. 6B) for all cultures examined, 
troponin C expressing cells with a flattened, spread straight edged morphology were present. While 
in all of CDC cultures and one CMSCLC cultures some cells were present that expressed nuclear NKX2.5. 
Representative images of NKX2.5 positive cells are shown in CDC derived cultures (Fig. 6C) and from 
the CMSCLC culture (Fig. 6D). The morphology of these cells differed from those in (Fig. 6A and 6B) as 
these cells had a more primitive rounded morphology. To further demonstrate cardiomyocyte 
differentiation, CMSCLC were differentiated for 3 weeks, and labelled for troponin C, cardiac actin or 
the striated muscle specific isoform of tropomyosin, α-tropomyosin, and imaged using Z-stack 
confocal microscopy. Maximum intensity z-stack projections demonstrated filamentous staining for 
all proteins (Fig 6 E-H). Additionally, maximum intensity volume projection of alpha-tropomyosin 
labelling clearly demonstrates the striated phenotype of these differentiating cells (Fig 6H, Hi). Note 
the absence of staining in negative controls (Supplemental Fig. 4A-C) and staining with all antibodies 
of cells of the AC10 cell line (Supplemental Fig. 4D). Analysis for percentage of cells expressing NKX2.5 
and Troponin C shows that the percentage of NKX2.5 expressing cells is lower than that of cells 
expressing Troponin C for both cell populations, with the percentages of cells expressing troponin C 
being higher in all cases for CMSCLC (98, 99 and 84%) compared with CDCs (86, 68, 63%)  (Fig 6I)  
Molecular analysis was used to examine the undifferentiated CMSCLC and after culture under cardiac 
differentiation conditions for expression of genes important for cardiogenesis both populations 
expressed MEF2C and GATA4 (Supplemental Fig. 5) 
 
Single cell transcriptomics analysis 
We examined CMSCLC derived from 3 patients, only cells that passed the quality control steps (see 
materials and methods) were included in the downstream analysis. The percentage of genes being 
expressed by cells in each culture was calculated (Fig. 7). B-actin was used as a housekeeping gene 
and was expressed by all cells. CD44 and tropomyosin were also expressed by all the cells analysed.  
GATA4 (percentage of cells expressing ranging from 82.5 -100%) VEGF (percentage of cells expressing 
ranging from 97.8-100%) TGF-β (percentage of cells expressing ranging from 96.5-100%) were also 
highly expressed. CDC73 was more variable, being expressed by 100% of the cells in one culture and 
by 95.6 and 79.3% of cells in the other two cultures. The expression of FGF-2 (100, 56.5 and 62%), HGF 
(18.5, 89.1, 41.3%), PCNA (98.5, 71.7, 55.1%), MEF2 (81.5, 86.9, 31%) and MCAM (58.4, 32.6, 27.5%) 
also varied between the different donors cultures. c-Kit expression was also variable between the 
different donor derived cultures with percentage of cells expressing being 3 and 10.8% and with one 
culture having no detectable expression (Fig. 7). No expression was observed for NXK.25 in any of the 
cells of the 3 donor cultures analysed (data not shown). 
 
Discussion 
The International Society for Cell therapy position paper (2006) set the minimum requirements for 
cells to be considered MSCs; as the ability to adhere to plastic under standard culture conditions, to 
express a number of cell surface antigens, to lack expression of a number of markers including the 
hematopoietic lineage markers CD45 and CD19, and to differentiate to osteoblasts, adipocytes and 
chondroblasts in culture [17]. This paper included the caveat that these criteria would need 
modification as our knowledge of MSCs increased. MSCs also have distinct cell morphology in vitro 
displaying a fibroblast-like morphology with cells showing parallel alignment and tapering of the 
fibroblast-like cellular protrusions [18]. CMSCLC displayed some of these characteristics; being plastic 
adherent in MSC culture conditions, having an MSC-like morphology and expressing MSC markers 
CD105, CD166 and CD44 [19]. CMSCLC differed from CS-CDCs, displaying higher levels of expression 
of these antigens. Although controversial, human MSC have been reported as being MHC I positive 
and having low/no expression of MHC II [20]. CDCs also express MHC I and lack expression of MHC II 
[21] and CMSCLC express MHC I and have low expression of MHC II. MSCs have been reported to have 
immunomodulatory properties, in part due to their ability to secrete the anti-inflammatory cytokine 
IL10 which has been suggested to be cardio-beneficial. In a rat model of myocardial infarction 
transplanted MSCs help reduce the inflammatory response and this was in part due to increased levels 
of IL10 [22]. We examined CMSCLC for IL10 expression and observed increased expression when cells 
where cultured for 14-17 days. In contrast to CS-CDCs, CMSCLC were unable to differentiate to the 
osteogenic lineage as they exhibit little/no matrix mineralization as indicated by the low/absence of 
alizarin red staining, while all CS-CDCs stained strongly for alizarin red. However, both cell populations 
exhibited low adipogenic differentiation and both failed to undergo chondrogenesis. This contrasts 
with BM-MSCs and sub-endocardial MSCs that have this tri-lineage differentiation potential [9]. These 
differences might be due to these being distinct cell populations, differences in tissue used for cell 
derivation (sub-endocardial MSC are derived from ventricle while CMSCLC are derived from atrial 
tissue), or due to differences in culture conditions used. CDCs and sub-endocardial MSC are grown out 
from tissue explants, whereas, CMSCLC are derived from single cell suspensions and CMSCLC are 
cultured in 5% CO2, 5% O2 whereas no information is provided on the oxygen conditions for the culture 
of sub-endocardial MSCs. We have reported on increased; derivation rates, osteogenic potential and 
cellular health of MSCs derived from haemarthrosis fluid cultured under low oxygen conditions versus 
those cultured under standard conditions [14], supporting the hypothesis that culture conditions may 
influence cell behavior or possibly support the preferential selection of a subset of cells within a 
heterogeneous cell population. Certain cardiac stem/progenitor cells have been shown to be 
preferentially located in distinct anatomical regions of the heart e.g. adult human cardiac side 
population cells have been reported to be confined to the left atrium and absent from the right [23]. 
In a molecular study of multiple mouse cardiac stem cell populations, a comparison was made 
between the mouse data and microarray data available in the public domain and CS-CDCs appeared 
to be closely related to BM-MSCs [24]. This might also account for the osteogenic response displayed 
by our CS-CDCs. In addition, sub-endocardial MSC were reported as being strongly positive for c-kit 
expression [9] and human CS-CDCs have been reported to express c-kit (about 18% of the total cell 
population) [25], while CMSCLC showed only low-level expression of c-kit. Identification of cardiac 
stem cells based on expression of c-kit alone has been brought into question. However, in a recent 
study it has been reported that within the CD45negc-kitpos cells found in the heart a small subpopulation 
of between 1-2% have the characteristics of true multipotent cardiac stem cells [26]. Therefore, the 
small percentage of c-kit expressing cells observed in CMSCLC cultures could represent such a 
population. The CMSCLC containing the highest percentage of c-kit expressing cells (2.6%) was also 
the only culture containing NkX2.5 expressing cells. PDGFR-αlpha has been reported to be expressed 
by progenitor cells in human fetal and diseased adult heart [27]. Therefore we also examined CMSCLC 
and observed that some expressed PDGFR-alpha. 
CMSCLC displayed other stem cell characteristics including the ability to form CFUs and be expanded 
in vitro. All CMSCLC cultures had similar potential with regard to cell doubling rates, while rates for 
CS-CDCs have been reported to be similar for cells generated from both non-transplant heart failure 
and transplant heart patient’s biopsy specimens [25]. Under cardiac differentiation culture conditions, 
both CS-CDC and CMSCLC had a phenotype previously reported for cardiomyocytes in culture [28]. 
Moreover, in these conditions all CS-CDC cultures but only one CMSCLC culture also contained a 
population of cells that expressed nuclear NXK2.5 and had an immature rounded morphology. These 
characteristics have previously been suggested to be indicative of a more primitive or early cardiac 
committed cell [29] and may suggest that the CS-CDC are more heterogeneous than the CMSCLC or 
that the CMSCLC are more mature. This is further support by our quantification of cells expressing 
troponin C that shows all CMSCLC containing higher numbers of Troponin C expressing cells than CS-
CDCs. In addition, we also observed that undifferentiated and differentiated CMSCLC expressed genes 
important for myocardial lineage development including MEF2C and GATA4 [30, 31]. Atrial appendage 
derived cardiac stem cells also express markers important for myocardial development and  even post-
induction of differentiation to a more mature cardiac lineage they continue to express MEF2C and 
GATA4 [32]. It is recognised that for MSCs derived from patient tissue, patient to patient variability 
does exist [33], and this could be responsible for the difference in the presence/absence of the NXK2.5 
expressing cells in the CMSCLC cultures. 
If cardiac stem/progenitors are to be used as a cellular therapy or indicator of heart health the level 
of cellular senescence needs to be determined. We examined CMSCLC derived from 3 different donors 
at passage 3 and observed the presence of between 5 to 15% senescent cells. Whether the presence 
of senescent cells within CMSCLC would prove to be a problem in utilizing these as a cellular therapy 
would need to be further explored. CSC expanded over approximately 113 days have been shown to 
contain small percentages of senescent cells (however the authors of this study did not provide data 
on % observed) and yet still deemed suitable for intracoronary perfusion in patients with heart failure 
[1].  
Human cardiac atrial appendage stem cells (CASCs), like CMSCLC, also fail to differentiate towards the 
osteogenic lineage. However, unlike the CMSCLC they also failed to differentiate towards the 
adipogenic lineage [34].  CASCs also lack expression of c-kit and CD44 [34], while most of our CMSCLC 
cultures contain small numbers of c-kit+ cells and express CD44. It is interesting to note that both atrial 
appendages can be used as a source of stem cells. Why the atrial appendages are such good sources 
of stem cells is not entirely understood, but they have a distinct developmental origin to the atria and 
display many trabeculae similar to ventricles [10]. They are also a source of atrial natriuretic peptide 
factor (ANP). Nppa, the gene encoding ANP, has been shown to be important for heart development 
as well as being reactivated in adult disease [35]. It may be these developmental/fetal links that make 
the appendages such rich sources of stem cells. A study of mouse left atrial appendage showed it to 
be a source of more than one type of cardiac progenitor population [36].  
As a cellular therapeutic, RAA-derived CMSCLC might have advantages over sub-endocardial derived 
MSCs (that readily differentiate to osteogenic, adipogenic and chondrogenic lineages, but remain 
primitive under cardiac differentiation conditions) and CS-CDCs or BM-MSCs as they lack the 
osteogenic potential of the former and the osteogenic and chondrogenic potential of the latter. This 
may have important implications for the use of CMSCLC as a potential cellular therapeutic as they 
could be less likely to contribute to cardiac calcification. The cause of this remains controversial, and 
while there is no evidence from clinical trials to date that cardiac derived cell transplantation causes 
calcification, there is evidence that cells with osteogenic and chondrogenic differentiation potential 
may be involved [37]. CMSCLC also differ to CS-CDCs as they do not require the rounds of 
harvesting/replating required to generate CS-CDCs [25].  
We did not observe spontaneous beating of CMSCLC cells under cardiac differentiation conditions; 
this may be a limitation of the technique used. Human CS-CDC cells also failed to beat in vitro unless 
co-cultured with neonatal rat ventricular myocytes [25], this was also the case with human CASCs [34].  
Our single cell analysis demonstrated that 100% of CMSCLC expressed CD44, a recognised marker of 
MSCs [19]. A large % of CMSCLC also expressed CDC73 which is associated with stem cell pluripotency 
[38]. Our single cell analysis also supported our standard PCR analysis showing that GATA4 and MEF2 
were also detectable at the single cell level. GATA4 was expressed by all CMSCLC for all three donors 
(100%, 84.7%, and 82.5%), while MEF2C expression was more variable with two cultures having high 
numbers of MEF2C positive cells (86.9% and 81.5%) but in the third only 31%. 100% of CMSCLC 
expressed Tropomyosin and 98.5%, 71.7 and 55% of CMSCLC expressed PCNA and nearly all expressed 
VEGF. Lower numbers of CMSCLC expressed MCAM (also known as CD146) with percentages varying 
from the highest at 58.4% to the lowest at 27.5%. CD146 has been reported to be expressed by a 
subpopulation of human MSCs from a telomerised bone marrow derived stromal cell line [39]. While 
in the heart it has been reported to be a marker of perivascular mesenchymal precursor cells [40]. 
Together this data suggests that CMSCLC are; proliferative, pluripotent and have some multi-lineage 
differentiation potential to other cells important in the heart. It also supports our in vitro culture 
observation of some CMSCLC being capable of expressing the endothelial cell marker CD34 under EC 
differentiation conditions. CMSCLC for all donors also expressed TGF-β. The role of TGF-β in the heart 
remains controversial it has been reported to contribute to heart failure but has also been suggested 
to be important for suppression of inflammation following myocardial infarction and been reported 
to be cardio-protective [41, 42]. CMSCLC also expressed VEGF (97.8 to 100 %) FGF2 (56.6, 62.0 and 
100%) and HGF (18.0, 41.3 and 89.1%), which have all been reported to be cardio-protective/cardio-
beneficial [42-44]. We also demonstrated using CMSCLC conditioned media that CMSCLC secrete a 
number of potentially cardio-beneficial factors including IL10, VEGF, FGF2 and TGFβ1. The role of MSC 
paracrine secreted factors that have protective/regenerative effects has now been demonstrated in 
several different tissues. In a rat neonatal hyperoxic lung injury model, human umbilical cord blood 
MSCs that secrete VEGF improved the survival rates on rat lung epithelial cells treated with hydrogen 
peroxide, to confirm this protective effect these cells where then used in an in vivo model of hyperoxic 
injury where is was again shown that the VEGF secreting MSCs protected against hyperoxia [45]. In a 
rat model of liver regeneration, BM-MSC alone or transfected with the VEGF gene were injected into 
the liver after major hepatic resection, both groups of cells engrafted into the liver where they 
secreted a number of paracrine factors including VEGF, FGF, TGFβ and HGF, and in both cases bile duct 
and liver hepatocyte proliferation occurred [46].    The paracrine activity of MSCs may be multi-modal 
as they have also been reported to be able to cause cardiomyocyte proliferation, be 
immunomodulatory and activate resident cardiac stem cells spared by cardiac injury [reviewed in 47]. 
Additionally, single cell analysis showed only a few CMSCLC expressed c-kit, data which supports the 
low percentages of c-kit expressing cells observed in the CMSCLC using FACS. Single cell profiling as a 
means of determining the paracrine activity of MSCs has previously been used successfully in a study 
on the role of MSCs in the infracted mouse heart, where the authors showed using a single cell 
approach that MSCs transplanted into injured heart expressed paracrine factors in vivo [48]. 
We have shown that CMSCLC cultured under cardiac differentiation conditions display the 
morphology and expressed some markers of more mature cardiac lineage-committed cells, even 
showing early striation formation. Similar changes have been observed in rat CDCs differentiated to a 
more mature cardiac lineage in vitro [49]. In addition CMSCLC secrete cardio-beneficial factors and 
have low/no adipogenic, chondrogenic or osteogenic differentiation potential, all qualities that should 
be advantageous for cells to be used therapeutically for cardiac regeneration. 
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Fig. 1 Morphology of different primary cells in culture. Representative brightfield images of cells in 
vitro at passage 3. (A) BM-derived MSCs, (B –D) show images from 3 different patients derived 
cultures of CMSCLC. Brightfield image showing morphology of human CDCs (E) Brightfield image of 
CMSCLC CFU (F). All scale bars = 100μm.   CMSCLC cultures derived from 3 different patient tissue 
samples were assessed for their ability to form CFUs under standard MSC culture conditions, BM was 
also assessed for CFU formation ability (G). The number of CFUs formed per culture at passage 1 are 
represented graphically. 
 
Fig. 2 Immunophenotyping of CS-CDC and CMSCLC. Representative images of FACS histograms 
showing results of immunophenotyping of CDC (n=3) and CMSCLC (n=3) using cell surface antigens 
of both hematopoietic lineage committed cells (CD45 and CD19) and those known to be expressed 
by MSCs (CD44, CD105, CD166). Controls are isotype control and unstained cells for both cell 
populations. All cells cultures were immunophenotyped at passage 3 
 
 
Fig. 3 FACS analysis for expression of MHCs and c-kit, and IHC analysis for CD34 expression, by 
CMSCLC. (A) Representative images of FACS histograms showing expression levels of MHC I and MHC 
II by CMSCLC (B) Table showing percentage of cells expressing MHCI and MHCII in 3 different patient 
derived CMSCLC cultures. (C) Representative image of FACS histogram showing expression level of c-
kit in CMSCLC and table showing percentage of cells expressing c-kit in 3 different patient derived 
CMSCLC cultures. (D) Cells from the same patient-derived CMSCLC cell line where cultured for 9 days 
under normal CMSCLC culture conditions (Control) and under Endothelial cells culture conditions (EC 
differentiation media) and were analyzed for the expression of CD34 (CD34 brown, cell nuclei blue). 
Note lack of CD34 in cells cultured under normal CMSCLC culture conditions (magnification x400). 
Scale bars = 100μm. All cultures were examined at passage 3 
 
 Fig. 4 Characterization of tri-lineage differentiation potential of CDC and CMSCLC at passage 3. 
Representative brightfield images from 3 different patients tissue samples of (A) CDC and (B) 
CMSCLC after 28 days in osteogenic culture conditions and prior to alizarin red staining 
demonstrates cellular proliferation and matrix deposition. Images of cells from the same samples 
but after being stained with alizarin red, staining reveals mineralisation of osteoid matrix within 
osteogenic cultures differentiated from CDCs (C) whereas (D) there is no mineralisation of culture 
matrix when CMSCLC were differentiated. Images of CDC (E) and CMSCLC (F) after 21 days under 
adipogenic culture conditions stained with Oil red O. Note the presence of red stained cells in both 
cultures. Images of cryosections of cell aggregates formed under pro-chondrogenic culture 
conditions after 14 days and after staining with Safranin O (counter stained with haematoxylin and 
fast green) for CDC (G) and CMSCLC (H). Note that while cell aggregates formed for both CDCs and 
CMSCLC chondrogenesis did not occur as evidenced by the absence of safranin O staining for 
sulphated glycosaminoglycans. Histological evaluation of cell aggregates shows lack of extracellular 
matrix deposition between cells and hence weak tissue structure. All scale bars = 100μm. BM-MSCs 
are shown after culture using the same differentiation protocols as for CDCs and CMSCLC and 
stained with alizarin red (I), Oil red O (J) and safranin O (K). Note BM-MSCs can differentiate to all 
three lineages. Scale bars for (I and J) = 100μm. Scale bar for (k) = 400 μm. 
 
 
Fig. 5 Quantification of CMSCLC p16 immunostaining. Representative image of p16 ICC showing 
results of staining of CMSCLC from patient 1179, p16 (green), all nuclei stained with DAPI (blue) scale 
bar = 100μm (A)  CMSCLC cultures derived from 3 different patient tissue samples were 
immunostained for the cell senescence marker p16 and counterstained with DAPI. The percentage 
of p16 positive cells within each culture was calculated by counting five independent fields within 
each culture. Box-plot analysis (SPSS) showed no significant difference in p16 expression between n= 




Fig 6 Characterization of cardiac differentiation potential of CDC and CMSCLC. Representative 
images of CDC (n=3 donors) and CMSCLC (n=4) donors at 14 days under cardiac differentiation 
culture conditions show that some of both the CDC (A) and (B) CMSCLC differentiated cells have a 
more mature cardiac morphology and express troponin C (green-Alexa fluor 488). While other cells 
from the same patient samples cultured under the same conditions but stained for expression of 
NKX2.5 have a more primitive rounded morphology and express nuclear NKX2.5 (NKX2.5 green-
Alexa fluor 488) in differentiated CDC (C) and differentiated CMSCLC culture (D). White arrows in (C) 
and (D) indicate cells shown in inserts of NKX2.5 staining without the DAPI overlay to shown the 
nuclear localization of NKX2.5. (E –H) Representative images of CMSCLC (n=4 donors) differentiated 
for 3 weeks and analyzed by confocal microscopy. (E) Maximum intensity projections of 
differentiated CMSCLC expressing Troponin C (green- Alexa fluor 488). (Ei) Higher magnification 
image demonstrates early striations, indicated by yellow arrow. (F)  Maximum intensity volume 
projection of differentiated CMSCLC labelled with Cardiac Actin (red- Alexa fluor 594). (G)  Maximum 
intensity volume projection of differentiated CMSCLC labelled with Alpha-tropomyosin (red- Alexa 
fluor 594). (H and Hi) Maximum intensity volume projection demonstrates striated pattern of Alpha-
Tropomyosin expression, indicated by yellow arrows. For all images nuclei labelled with DAPI-Blue. 
Scale bars were either 20 or 50 μm as indicated. (I) Bar chart showing percentage of cells expressing 
NXK2.5 or troponin C, n= 3 for both CDC and CMSCLC cultures analyzed. 
 
Fig 7 Graphical representation of Single cell data representing percentage of CMSCLC expressing 
genes of interest for n=3 donors. The percentage of cells expressing each gene is shown. 
 Supplemental Fig. 1 Analysis of doubling time of CMSCLC cultures. Cell population doublings per day 
were calculated for 3 patient derived cultures, with values presented as the average rate of 
population doubling over three cell culture passages. No significant differences in cell doubling rates 
were observed between the 3 different cultures 
 
Supplemental Fig. 2 FACS analysis for expression of PDGFR-alpha by CMSCLC.  Representative 
images of FACS histograms showing unstained CMSCLC (A) and cells stained for expression of 
PDGFR-alpha (B). 
 
Supplemental Fig. 3 Bar chart showing ELISA detected fold changes in IL10, VEGF, FGF2 and TGFβ1 
expression levels from CMSCLC cultured under standard CMSCLC conditions over time compared 
with control media (A). Note increased expression for all factors at day 14 and 17 compared with 
control. Note increases in fold change are significant for all factors at both time point with the 
exception of Il10 and 14 days which was not significantly (NS) different (B). 
 
Supplemental Fig. 4 ICC controls for staining of CMSCLC. 
ICC analysis showing results of CMSCLC stained using secondary antibodies only (no primary) for 
Troponin C, NKX2.5 and tropomyosin (A). All nuclei are stained with DAPI (Blue) A and B, Scale bars = 
20µm; C, scale bar = 50µm.  ICC analysis showing results of staining of the AC10 cell line (D) for 
expression of Troponin C (green), Alpha-tropomyosin (red), NXK 2.5 (green) and Cardiac Actin (red). 
All nuclei are stained with DAPI (Blue). Scale bars = 25 µm.  
 
Supplemental Fig. 5 Transcriptional expression of MEF2C and GATA4 in undifferentiated and 
differentiated CMSCLC.  Results of RT-PCR analysis of CMSCLC derived from 3 different patients. 
Note that expression of mRNA from both genes can be detected in both undifferentiated CMSCLC 
and cells from the same cultures after differentiation under cardiomyocyte differentiation 
conditions. β-actin was used as a loading control. Abbreviations: UD=undifferentiated, 
D=differentiated 
 
Supplemental Table 1 TaqMan® primers used in single-cell qPCR 
 
 
  
 
  
 
 
 
 
 
  
 
 
 
  
 
  
 
 
 
 
 
  
 
  
 
 
